BLUEPRINT MEDICINE STOCK DRIVER
Pralsetinib will join Roche’s already approved lung cancer medicines including, Alecensa (alectinib), Rozlytrek (entrectinib), Tecentriq (atezolizumab), Avastin (bevacizumab), and Tarceva (erlotinib), and will aid in the company’s understanding of driver mutations in lung cancer, the press release said. The companies will share global development expenses based on pre-specified cost-sharing percentages and will share profits and losses in the US.
Under the agreement, Blueprint Medicines will obtain an upfront cash payment of $675 million, a $100 million equity investment in Blueprint Medicines’ common stock, and up to $927 million in contingent development, regulatory, and sales-based milestones and royalties on net product sales outside the United States, according to a Roche press release. Roche and Blueprint Medicines Corporation, a precision therapy company headquartered in Cambridge, MA, announced on Jthat they are entering into a licensing and collaboration agreement for the co-commercialization rights to pralsetinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of RET-altered non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancer, for up to $1.7 billion.
0 kommentar(er)
